Quantcast

Latest Antivirals Stories

2014-04-02 08:33:17

MOSCOW, April 2, 2014 /PRNewswire/ -- Hepatera Ltd. [http://www.hepatera.ru/?ln=en ] announces initiation of a clinical trial investigating Myrcludex B in chronically HBV infected patients who are also infected with hepatitis delta virus (HDV). Hepatera is financed by Maxwell Biotech Venture Fund [http://www.maxwellbiotech.com ] formed with the participation of RVC [http://www.rusventure.ru/en ] - Russia's government fund of venture capital funds. Hepatera was...

2014-04-02 08:32:34

OPTIMIST represents the first Phase 3 studies of the two treatments in a regimen without interferon and ribavirin CORK, Ireland, April 2, 2014 /PRNewswire/ -- Janssen R&D Ireland (Janssen) announced today that two Phase 3 trials are recruiting patients to examine the efficacy and safety of the NS3/4A protease inhibitor simeprevir in combination with the nucleotide inhibitor sofosbuvir for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection in treatment-naive and...

2014-03-28 08:27:04

ASHEVILLE, N.C., March 28, 2014 /PRNewswire/ -- It's hard to imagine heavyweight hematologists publicly squaring off in support of an off-label blood cancer drug. And yet, today, that's exactly what happened in an "Open Letter to the MPN Community of the United States," (http://mpnforum.com/an-open-letter/) published in the April issue of MPNforum Magazine. (www.mpnforum.com) Photo - http://photos.prnewswire.com/prnh/20140328/PH92830-a Photo -...

2014-03-26 23:28:09

Markets Research Reports.biz added deep and professional market research reports on "Global Cloud Computing: Infrastructure, Platforms, and Services 2014 - 2019" Market Analysis and Overview Albany, NY (PRWEB) March 26, 2014 Cloud is an enabler of business process change as it facilitates enterprise to realize key benefits including expenditure reduction (CapEx and OpEx), service development and delivery efficiencies, and greater flexibility to meet evolving business needs....

2014-03-25 23:30:00

Markets Research Reports.biz added deep and professional market research reports on "Global Cancer Vaccines Competitor Analysis And Market Research" Market Analysis and Overview. Albany, NY (PRWEB) March 25, 2014 The present Competitive Intelligence report about Cancer Vaccines provides a competitor evaluation in the field of novel prophylactic and therapeutic vaccines to fight cancer as of March 2014. Purchase of the downloadable pdf report includes a 6-month online access to...

2014-03-25 23:29:51

Markets Research Reports.biz added deep and professinal market research reports on "Global Endoscopy Market Report 2014" Market Analysis and Overview. Albany, NY (PRWEB) March 25, 2014 Endoscopy is a minimally invasive diagnostic medical procedure in which a tube like instrument, known as endoscope, is used to look inside the body and examine organs. There are many different types of endoscopes available in the market; some are flexible and rigid while few are in a form of...

2014-03-24 08:28:25

CORK, Ireland, March 24, 2014 /PRNewswire/ -- New data from the clinical development program for Janssen's protease inhibitor simeprevir in the treatment of genotype 1 chronic hepatitis C virus (HCV) in adult patients with compensated liver disease will be presented at The International Liver Congress(TM) of the European Association for the study of the Liver (EASL). The International Liver Congress(TM) 2014 will take place from April 9-13 in London....

2014-03-24 04:22:12

NORTH CHICAGO, Ill., March 24, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present new data from its phase III hepatitis C development program at the 2014 International Liver Congress(TM) (ILC) in London, April 9-13. Detailed results from the SAPPHIRE-I, SAPPHIRE-II, PEARL-III, and TURQUOISE-II studies will be presented at the ILC on April 10-12. In presentations at the ILC, investigators will share detailed data results of four studies from AbbVie's phase III clinical trial program, the...

2014-03-10 08:28:58

ROCKVILLE, Md., March 10, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, announced today that the U.S. Patent & Trademark Office has issued U.S. Patent No. 8,658,627 entitled, Pregnancy Hormone Combination for Treatment of Autoimmune Diseases, to the Regents of the University of California (UCLA). The patent includes claims to...

2014-03-03 16:25:42

-- SVR(12) rates of 99 percent with and without ribavirin were achieved in genotype 1b patients new to treatment BOSTON, March 3, 2014 /PRNewswire/ -- The first detailed results from AbbVie's (NYSE: ABBV) pivotal phase III study, PEARL-III, were presented today as part of the 21st Conference on Retroviruses and Opportunistic Infections (CROI) press conference and will also be presented as a late-breaker at the conference on March 4. PEARL-III evaluated the efficacy and safety of 12...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.